



LEAPING FORWARD ONCOLOGY UROLOGICAL CANCER SESSION

PROGRAMME

12 MAY 2017 > AUDITORIUM 2

08:00 AM Opening & registration

08:15 AM Welcome and Introduction
Kris Maes (PT) | Francisco Mascarenhas (PT)

08:30 AM PROSTATE CANCER

Round Table 1 | Image-guided diagnosis and treatment in prostate cancer
Chairmen: Adalgisa Guerra (PT) | Ferran Guedea (SP)

For how much longer will we be using the Gleason score? New kids on the block
Fernando Algaba Arrea (SP)

Impact of MRI MP and MRI-targeted biopsies in diagnosis of prostate cancer
Geert Villeirs (BE)

Role of MRI in staging and management of advanced prostate cancer
Nina Tunariu (UK)

Discussion

09:30 AM Round Table 2 | Controversies in treatment of low and medium risk prostate cancer: focal therapy
Chairmen: Patrick Kupelian (US) | Rafael Coelho (BR)

HIFU focal therapy
Eric Potiron (FR)

Radiation focal therapy
Ferran Guedea (SP)

10:15 AM Coffee Break

10:45 AM Round Table 3 | How does the future treatment of low risk and intermediate risk PC looks like

Chairmen: Ferran Guedea (SP) | Arnulf Stenzl (DE)

For the radiation oncologist

Patrick Kupelian (US)

For the surgeon

Steven Joniau (BE)

11:30 AM Debate | High risk prostate cancer: the future

Chairmen: Kris Maes (PT) | Steven Joniau (BE) | Filomena Pina (PT) | Luís Campos Pinheiro (PT)

Radiation therapy

Patrick Kupelian (US)

Radical prostatectomy

Arnulf Stenzl (DE)

Discussion

12:15 PM TESTICULAR CANCER

Chairman: José Luís Passos Coelho

Surgical issues in testicular cancer:

a) Adjuvant RPLND for whom?

b) Role of surgery for residual disease after chemotherapy

Rafael Coelho (BR)

01:00 PM Lunch

02:00 PM PROSTATE CANCER

Round Table 4 | The management of recurrent prostate cancer after local treatment
Chairmen: Arnulf Stenzl (DE) | Patrick Kupelian (US)

Salvage prostatectomy/lymphadenectomy: when and how
Steven Joniau (BE)

Salvage radiotherapy: when and how
Ferran Guedea (SP)

Systemic therapy: when and how
Robert Jones (UK)

03:00 PM Round Table 5 | Future perspectives for treatment of advanced disease
Chairmen: Fabio Schutz (BR) | Rosário Vieira (PT)

Management of mCRPC: chemotherapy for hormone naïve metastatic patients
Robert Jones (UK)

The power of precision medicine: PSMA radioligand therapy (PRLT) of end-stage prostate cancer patients selected by PSMA PET/CT
Aviral Singh (DE) | Richard Baum (DE)

04:00 PM Coffee Break

04:30 PM BLADDER CANCER

Chairmen: Tomé Matos Lopes (PT) | Francisco Mascarenhas (PT)

Current and future treatment of NMIBC
Oscar Rodriguez (SP)

Who profits from neo-adjuvant chemotherapy for MIBC
Fabio Schutz (BR)

Multimodal treatment of MIBC: external beam radiotherapy and robotic limited surgery plus brachytherapy for bladder cancer
Elzbieta van der Steen-Banasik (NL)

Discussion

06:00 PM Closing remarks
TBD

Directors: Francisco Mascarenhas | Kris Maes

Faculty: Adalgisa Guerra | Aviral Singh | Arnulf Stenzl | Elzbieta van der Steen-Banasik | Eric Potiron | Fabio Schutz
Fernando Algaba Arrea | Ferran Guedea | Filomena Pina | Geert Villeirs | José Luís Passos Coelho | Luís Campos Pinheiro
Nina Tunariu | Oscar Rodriguez | Patrick Kupelian | Rafael Coelho | Richard Baum | Robert Jones | Rosário Vieira | Steven Joniau
Tomé Matos Lopes